Cangrelor
Cangrelor is a pharmaceutical drug with 25 clinical trials. Currently 3 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
7
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.3%
15 of 18 finished
16.7%
3 ended early
3
trials recruiting
25
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Clinical Trials (25)
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
Cangrelor Neonatal PK/PD and Safety Study
Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry
Platelet Inhibition to Target Reperfusion Injury
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
Dutch Cangrelor Registry
Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size
Cangrelor to Clopidogrel or Prasugrel Transition Study
Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)
Add-on Cangrelor in STEMI-triggered Cardiac Arrest
Cangrelor Prasugrel Transition Study
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 25